TY - JOUR
T1 - Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population
T2 - Double-Blinded Randomized Clinical Trial
AU - Herardi, Ryan
AU - Syam, Ari Fahrial
AU - Simadibrata, Marcellus
AU - Setiati, Siti
AU - Darnindro, Nikko
AU - Abdullah, Murdani
AU - Makmun, Dadang
N1 - Publisher Copyright:
© 2020 Asian Pacific Organization for Cancer Prevention.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.
AB - OBJECTIVE: The aim of this study was to compare the effectiveness of 10-day course of triple therapy versus a 14-day course in the treatment of H.pylori infection in an Indonesian population. METHODS: A double-blinded randomized clinical trial was included patients, Indonesian population, with H.pylori infection conducted in Cipto Mangunkusumo Hospital, Jakarta; Cilincing District General Hospital, Jakarta; and West Nusa Tenggara General Hospital, Mataram, during October 2016 - April 2017. Patients were randomized to be given triple therapy as Rabeprazole 20 mg, Amoxicillin 1,000 mg, and Clarithromycin 500 mg twice daily, for 14 days or 10 days plus 4 days placebo. Eradication was evaluated with UBT at least 4 weeks after completion the therapy. RESULTS: A total of 75 patients (38 in the 14-day group and 37 in the 10-day group) were included to the study. In the intention-to-threat analysis, eradication rate was 67.6% (95% CI. 52.5%-82.6%) for the 10-day group versus 86.8% (95% CI. 76.0%-97.5%) for the 14-day group (p = 0.046), whereas per protocol analysis obtained 73.5% (95% CI. 58.6%-88.3%) for the 10-day versus 91.9% (95% CI. 84.1%-99.6%) in the 14-day group (p = 0.039). Adverse events were not significantly different between the two groups. CONCLUSION: A 14-day course was more effective than 10-day course of triple therapy as first-line for eradication of H.pylori infection in an Indonesian population.
KW - Duration
KW - eradication
KW - Helicobacter pylori
KW - Indonesian population
KW - Triple therapy
UR - http://www.scopus.com/inward/record.url?scp=85078342241&partnerID=8YFLogxK
U2 - 10.31557/APJCP.2020.21.1.19
DO - 10.31557/APJCP.2020.21.1.19
M3 - Article
C2 - 31983158
AN - SCOPUS:85078342241
SN - 1513-7368
VL - 21
SP - 19
EP - 24
JO - Asian Pacific journal of cancer prevention : APJCP
JF - Asian Pacific journal of cancer prevention : APJCP
IS - 1
ER -